Presence of the posterior pituitary bright spot sign on MRI in the general population: a comparison between 1.5 and 3T MRI and between 2D-T1 spin-echo- and 3D-T1 gradient-echo sequences
To describe the prevalence of the posterior pituitary bright spot (PPBS) in the general population on 1.5 and 3T MRI examinations and on 2D-T1 spin-echo (SE) and 3D-T1 gradient-echo (GE) sequences.
Materials and methods
1017 subjects who received an MRI of the brain for aspecific neurological complaints were included. MRI was performed on 1.5T in 64.5% and on 3T in 35.5% of subjects. Presence of the PPBS was evaluated on sagittal 2D T1-SE echo images with slice thickness 3 mm in 67.5% and on sagittal 3D T1-GE with slice thickness 0.9 mm in 32.5% of subjects.
The PPBS was detectable in 95.9% of subjects. After correction for sex and age, no statistically significant difference could be seen concerning PPBS detection between 1.5 and 3T MRI examinations (p = 0.533), nor between 2D T1-SE and 3D T1-GE sequences (p = 0.217). There was a statistically significant association between increasing age and the absence of the PPBS (p < 0.001). The PPBS could not be identified in 6.2% of male subjects, compared to 2.2% of female subjects (p = 0.01).
Absence of the PPBS can be seen in 4.1% of patients undergoing MRI of the brain for non-endocrinological reasons. Neither field-strength nor the use of a thick-sliced 2D T1-SE versus a thin-sliced 3D T1-GE sequence influenced the detectability of the PPBS. There is a statistically significant association between increasing age and male sex and the absence of the PPBS.
KeywordsPituitary bright spot MRI Posterior pituitary Vasopressin
- 3D-MP RAGE
3D-magnetization prepared rapid gradient-echo
Posterior pituitary bright spot
The authors would like to thank Dr. M. Van Bockstal (Department of Anatomic Pathology, UZ Gent, Belgium) for her help with the statistical analysis.
Compliance with ethical standards
Conflict of interest
Martin Wiesmann has received grants from Stryker Neurovascular. Siemens Healthcare, personal fees from Stryker Neurovascular. Silkroad Medical. Siemens Healthcare. Bracco, and non-financial support from Codman Neurovascular. Covidien. Abbott. St. Jude Medical. Phenox. Penumbra. Microvention/Terumo. B. Braun. Bayer. Acandis. ab medica. The other authors have nothing to disclose.
For this type of study formal consent is not required.
This is a retrospective imaging analysis and patients cannot be identified based on the data and images provided, so no informed consent was obtained.
- 1.Osborn AG (2013) Osborn’s brain, imaging, pathology, and anatomy. Amirsys Pub., Salt Lake City, pp 683–687Google Scholar
- 11.Diabetes Data and Statistics (2017) Centers for Disease Control and Prevention Website. https://www.cdc.gov/diabetes/data/index.html. Accessed 05 June 2017